NTV Asset Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

NTV Asset Management’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,950	Closed	-$102K	–	264
2023 Q1	$102K	Buy	12,950 +345	+3%	+$1.2K	0.02%	252
2022 Q4	$11.3K	Buy	+12,605	New	+$12.9K	﹤0.01%	247

Other funds holding BLPH

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NTV Asset Management's BLPH Position: Q2 2023 in Review

NTV Asset Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2023, closing a stake of 12,950 shares — an estimated $102K sold.

NTV Asset Management first reported a position in BLPH in Q4 2022 and held it in 2 quarters. The position peaked at $102K in Q1 2023. 23 funds tracked by Wall St. Rank hold BLPH as of Q2 2023.

NTV Asset Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
NTV Asset Management sold 12,950 Bellerophon Therapeutics, Inc. shares in Q2 2023, an estimated $102K.
NTV Asset Management first reported a position in Bellerophon Therapeutics, Inc. in Q4 2022 and held it in 2 quarters.
NTV Asset Management's Bellerophon Therapeutics, Inc. position peaked at $102K in Q1 2023.
23 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2023.

Based on NTV Asset Management's 13F filing for Q2 2023, filed 2 Aug 2023.